Stem‐cell mobilization of healthy sibling donors with pegfilgrastim—A prospective open‐label phase II trial ( EudraCT no: 2005‐004971‐39)-Reference-Cited by-同舟云学术

Stem‐cell mobilization of healthy sibling donors with pegfilgrastim—A prospective open‐label phase II trial ( EudraCT no: 2005‐004971‐39)

Published:2021-12-10 Issue:1 Volume:62 Page:157-164
ISSN:0041-1132
Container-title:Transfusion
language:en
Short-container-title:Transfusion

Author:

Vucinic Vladan¹^ORCID,Jentzsch Madlen¹,Leiblein Sabine¹,Bach Enrica¹,Remane Yvonne²,Schulze‐Forster Kai³,Cross Michael¹,Pönisch Wolfram¹,Schwind Sebastian¹,Franke Georg‐Nikolaus¹,Platzbecker Uwe¹,Niederwieser Dietger¹

Affiliation:

1. Leipzig Medical Center, Clinic for Hematology and Cell Therapy University Clinic Leipzig Leipzig Germany

2. Leipzig Medical Center, Pharmacy University Clinic Leipzig Leipzig Germany

3. CellTrend GmbH Luckenwalde Germany

Publisher

Wiley

Subject

Hematology,Immunology,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/trf.16761

Reference25 articles.

1. Comparison between once a day vs twice a day G-CSF for mobilization of peripheral blood progenitor cells (PBPC) in normal donors for allogeneic PBPC transplantation

2. Filgrastim (r-metHuG-CSF): the first 10 years

3. A randomized comparison of once versus twice daily recombinant human granulocyte colony‐stimulating factor (filgrastim) for stem cell mobilization in healthy donors for allogeneic transplantation;Kröger N;Br J Haematol,2000

4. Pegfilgrastim

5. Randomized, Dose-Escalation Study of SD/01 Compared With Daily Filgrastim in Patients Receiving Chemotherapy

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hematopoietic cell transplantation (HCT) in MDS patients of older age;Leukemia & Lymphoma;2024-02-05

2. The Impact of Pre-Apheresis Health Related Quality of Life on Peripheral Blood Progenitor Cell Yield and Donor's Health and Outcome: Secondary Analysis of Patient-Reported Outcome Data from the RDSafe and BMT CTN 0201 Clinical Trials;Transplantation and Cellular Therapy;2022-09